Incyte vs Medpace: revenue, profit, margins and growth compared
Incyte brought in $5.1B of revenue in fiscal 2025, Medpace $2.5B in fiscal 2025. Revenue changed by +21.2% at Incyte and +20.0% at Medpace on the year before, so Incyte grew faster. Incyte kept 25.0% of its revenue as net profit, Medpace 17.8%.
Fiscal years as each company reports them; the two may end in different months.
Questions about Incyte and Medpace
Which is bigger by revenue, Incyte or Medpace?
Incyte is bigger by revenue: $5.1B in fiscal 2025, against $2.5B for Medpace in fiscal 2025.
Which keeps more of its revenue as profit, Incyte or Medpace?
Incyte had a net margin of 25.0% in fiscal 2025; Medpace had 17.8% in fiscal 2025.
Which grew revenue faster, Incyte or Medpace?
In their latest fiscal years revenue changed by +21.2% at Incyte and +20.0% at Medpace.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.